drugset / Trial / NCT02289365

Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

NCT02289365 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

This trial is designed as a multicenter, double-blinded, randomized, placebo controlled study to assess the safety and efficacy of JBM-TC4 for the prevention and treatment of acute radiation-induced dermatitis in breast cancer patients receiving radiotherapy.

Timeline

Start
2014-11
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject JBM-TC4 Unknown 2000 mg Oral
Subject JBM-TC4 Unknown 3000 mg Oral

Indications